Form 4 Filing for Sally E. Blount

Sally E. Blount, a director at Abbott Laboratories, acquired 2,286 common shares without par value on April 24, 2026. This award was granted under the Abbott Laboratories 2017 Incentive Stock Program and will be paid in shares upon separation from service, death, or change in control. Following this transaction, Ms. Blount holds 36,344 shares. The filing also includes a Power of Attorney document authorizing specific individuals to act on Ms. Blount's behalf for SEC filings, including those related to Rule 144 and Section 16(a) of the Securities Exchange Act of 1934. This authorization remains in effect until Ms. Blount is no longer required to make such filings or revokes the authorization in writing.